OPKO Health (NASDAQ:OPK) Trading Down 3.1%

OPKO Health, Inc. (NASDAQ:OPK)’s share price traded down 3.1% during trading on Wednesday . The company traded as low as $3.72 and last traded at $3.72. 66,438 shares changed hands during trading, a decline of 99% from the average session volume of 6,188,090 shares. The stock had previously closed at $3.84.

Separately, LADENBURG THALM/SH SH assumed coverage on shares of OPKO Health in a research note on Monday. They set a “buy” rating and a $7.00 price target on the stock.

The firm has a 50 day simple moving average of $3.85. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.09 and a current ratio of 1.48. The firm has a market cap of $2.53 billion, a price-to-earnings ratio of 19.84 and a beta of 1.77.

OPKO Health (NASDAQ:OPK) last released its earnings results on Wednesday, April 28th. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of $0.05. OPKO Health had a return on equity of 7.34% and a net margin of 6.83%. The firm had revenue of $545.20 million during the quarter, compared to analyst estimates of $503.00 million. Sell-side analysts predict that OPKO Health, Inc. will post 0.09 earnings per share for the current year.

In other OPKO Health news, CEO Phillip Md Et Al Frost bought 25,000 shares of the company’s stock in a transaction that occurred on Thursday, May 6th. The shares were purchased at an average price of $3.91 per share, with a total value of $97,750.00. Following the completion of the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $11,999,598.41. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Jon R. Cohen purchased 50,000 shares of the business’s stock in a transaction on Monday, May 10th. The stock was acquired at an average price of $3.81 per share, for a total transaction of $190,500.00. Following the completion of the purchase, the senior vice president now owns 125,000 shares of the company’s stock, valued at $476,250. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 775,000 shares of company stock valued at $2,840,500. Corporate insiders own 41.47% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Baillie Gifford & Co. acquired a new stake in OPKO Health during the first quarter worth approximately $31,000. Quantbot Technologies LP grew its holdings in shares of OPKO Health by 129.9% during the first quarter. Quantbot Technologies LP now owns 7,294 shares of the biotechnology company’s stock worth $31,000 after purchasing an additional 4,122 shares during the last quarter. Matrix Asset Advisors Inc. NY acquired a new stake in shares of OPKO Health during the fourth quarter worth about $40,000. Beacon Pointe Advisors LLC acquired a new stake in shares of OPKO Health in the 4th quarter valued at about $40,000. Finally, Linscomb & Williams Inc. purchased a new position in OPKO Health during the 4th quarter worth approximately $43,000. 27.79% of the stock is owned by hedge funds and other institutional investors.

About OPKO Health (NASDAQ:OPK)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units, as well as 4Kscore prostate cancer testing services.

Further Reading: Market Timing – The Benefits and the Danger

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.